Next Generation Sequencing Market Shows Expected Trend to Guide from 2018-2026 with Growth Analysis By Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V.,Illumina Inc.

Coherent Market Insights has announced the addition of the “Next Generation Sequencing Market, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing and Others), by Application (Drug Discovery, Personalized Medicine and Genetic Screening, Disease Diagnosis, Agriculture and Animal Research and Others), by End User (Hospital, Research Centers, Pharma and Biotech Firms and Others), and by Region - Global Industry Insights, and Forecast to 2025”, The report classifies the Next Generation Sequencing Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Download PDF Brochure of This Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/158

Next Generation Sequencing (NGS) is a powerful, flexible, and indispensable biological tool that is used in several areas of biological study. NGS technologies help in generating genome-wide sequence data in a couple of days. These technologies are highly parallelized allowing to sequence thousands to millions of molecules at the same time. The main advantage of these platforms is determination of the sequenced data from amplified single DNA fragments, avoiding the need for cloning of DNA fragments.

NGS has large number of applications, enabling rapid technological advances across several fields in biological science. The technology has enabled researchers to gain significant knowledge in public health studies and epidemiology, to sequence viruses and bacteria and help detect causes that may contribute to virulence. Furthermore, in gene expression research, next generation sequencing of RNA replace microarray analysis, allowing researchers to see RNA expression sequence. This RNA sequencing can provide information on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.

Market Dyanamics

Major factors driving growth of the next generation sequencing market are early detection of cancer and infectious diseases and increasing partnership among academic and industry partnerships for research and development. For academic institutions, these collaborations help in commercialization of their discoveries from basic research to medical products. For instance, in March, 2018, Cofactor Genomics, a U.S.-based developer of Cofactor Paragon (RNA analysis tool) signed agreement with National Cancer Institute, and other three other pharma and academic institutes to show clinical ability of its product.

Increasing prevalence of cancer and infectious diseases and ability of NGS platforms to detect cancers and infectious diseases are expected to drive growth of the next generation sequencing market during the forecast period. The use of NSG for study of cancer cells mutations is increasing and the implementation of this technology has considerably aided in early diagnosis of diseases. In the U.S., over 1.69 million new cancer cases were detected in 2016; whereas the global incidence of cancer was around 14 million new cases in 2012 and an annual 19.3 million cases are estimated by 2025.

Request For A Sample Copy of This Research Report : https://www.coherentmarketinsights.com/insight/request-sample/158

Rising Demand For Early Detection Of Cancer And Infectious Diseases To Drive Growth Of The Ngs Market

The chances of successful treatment increase when cancer and infectious diseases are detected at the early stage. One of the major factors that drive growth of the next generation sequencing market is the rising prevalence of cancer and other infectious diseases. According to the World Health Organization (WHO), in 2012, new cases of cancer was around 14 million and the incidence is estimated to increase to 70% by 2030.

As per statistics published by National Cancer Institute (NCI), in 2016, 1,685,210 new cases of cancer were diagnosed in the U.S. alone. In 2015, WHO reported 8.8 million deaths occurred due to cancer. According to American Cancer Society (ACS), in 2017, around 161,360 cases of prostate cancer were reported in the U.S alone. ACS, in 2015, also reported 4.5 million new cancer cases in China and the number is expected to increase to 7.6 Mn by 2020. Morbidity cases in tuberculosis, salmonella, and meningococcal disease was as high as 90,000 in the U.S. in 2016. Therefore, increasing demand for early diagnosis of cancer and infectious diseases, to aid in better outcome, is in turn expected to aid in growth of the market over the forecast period.

Competitive Landscape

Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford Nanopore Technologies, and Beijing Genomics Co. Ltd.

Request For Customization Of This Research Report : https://www.coherentmarketinsights.com/insight/request-customization/158

Detailed Segmentation:

Global Next Generation Sequencing Market, By Technology:
Whole Genome Sequencing
Whole Exome Sequencing
RNA Sequencing
Targeted Re-sequencing
Others

Global Next Generation Sequencing Market, By Application:
Drug Discovery
Personalized Medicine and Genetic Screening
Disease Diagnosis
Agriculture and Animal Research
Others

Global Next Generation Sequencing Market, By End User:
Hospital
Research Centers
Pharma and Biotech Firms
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.